Mahesh Seetharam
Overview
Explore the profile of Mahesh Seetharam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
499
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papke Jr D, Chrisinger J, French C, Crymes A, Krivak T, Estape R, et al.
Mod Pathol
. 2025 Feb;
38(5):100729.
PMID: 39921028
NUT fusion-associated cancers are heterogeneous and include NUT carcinoma and an emerging group with non-BRD4/BRD3/NSD3 fusion partners. In this study, we characterized 11 tumors harboring MAD::NUT fusions (10/11 in female...
2.
Norman A, Seetharam M, Allred J, Kong J, Opyrchal M, Ma W, et al.
BJC Rep
. 2025 Jan;
3(1):1.
PMID: 39809926
Background: Based on preclinical data showing addition of CDK4/6 inhibitors to gemcitabine was synergistic, ribociclib was evaluated in combination with gemcitabine to determine the maximum tolerated dose (MTD) and dose...
3.
Stoff R, Markovic S, McWilliams R, Kottschade L, Montane H, Dimou A, et al.
Melanoma Res
. 2024 Aug;
34(6):510-518.
PMID: 39207855
Melanoma is the deadliest form of skin cancer. The median age at diagnosis is 66. While most patients are treated with immunotherapy, the use of targeted therapy is a valid...
4.
Li Y, Huang J, Chen X, Ye Y, Du X, Voutsadakis I, et al.
Front Oncol
. 2024 Jul;
14:1416241.
PMID: 39055564
Background: Undifferentiated small round-cell sarcomas (uSRCSs) are a subgroup of sarcomas that are difficult to diagnose. Some uSRCSs have specific gene re-arrangements, but others do not. Currently, there is no...
5.
Karigyo C, Pessoa B, Nicacio S, Terwilliger E, Costa P, Reck Dos Santos P, et al.
Braz J Cardiovasc Surg
. 2024 Jul;
39(6):e20230405.
PMID: 39038269
Cardiac tumors are rare and encompass a variety of presentations. Clinica symptoms are usually nonspecific, but they can present as obstructive, embolic, or constitutional symptoms. Treatment options and prognosis vary...
6.
Cote G, Conley A, Attia S, Van Tine B, Seetharam M, Chen Y, et al.
Cancer
. 2024 Jul;
130(22):3845-3854.
PMID: 38985843
Background: This was a single-arm, phase 2 clinical trial of Bavarian Nordic (BN)-Brachyury vaccine plus radiotherapy (RT) designed to determine the objective response rate (ORR), progression-free survival (PFS), and safety...
7.
Seetharam M, Norman A, Allred J, Kong J, Opyrchal M, Ma W, et al.
Res Sq
. 2024 May;
PMID: 38746220
Background: Based on preclinical data showing addition of CDK4/6 inhibitors to gemcitabine is synergistic, ribociclib was evaluated in combination with gemcitabine to determine the maximum tolerated dose (MTD) and dose...
8.
Emiloju O, Yin J, Koubek E, Reid J, Borad M, Lou Y, et al.
Invest New Drugs
. 2024 Jan;
42(1):127-135.
PMID: 38270822
Navitoclax (ABT-263) is an oral BCL2 homology-3 mimetic that binds with high affinity to pro-survival BCL2 proteins, resulting in apoptosis. Sorafenib, an oral multi kinase inhibitor also promotes apoptosis and...
9.
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
Ingham M, Allred J, Chen L, Das B, Kochupurakkal B, Gano K, et al.
J Clin Oncol
. 2023 Jul;
41(25):4154-4163.
PMID: 37467452
Purpose: Uterine leiomyosarcoma (uLMS) is an aggressive subtype of soft-tissue sarcoma with frequent metastatic relapse after curative surgery. Chemotherapy provides limited benefit for advanced disease. Multiomics profiling studies have identified...
10.
Huff D, Horsley R, Seetharam M, Larsen B
Am J Med
. 2023 May;
136(9):e171-e172.
PMID: 37148991
No abstract available.